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Abstract: Neurosteroids are a family of compounds that are synthesized in principal excitatory neurons
and glial cells, and derive from the transformation of cholesterol into pregnenolone. The most studied
neurosteroids—allopregnanolone and allotetrahydrodeoxycorticosterone (THDOC)—are known
to modulate GABAA receptor-mediated transmission, thus playing a role in controlling neuronal
network excitability. Given the role of GABAA signaling in epileptic disorders, neurosteroids have
profound effects on seizure generation and play a role in the development of chronic epileptic
conditions (i.e., epileptogenesis). We review here studies showing the effects induced by neurosteroids
on epileptiform synchronization in in vitro brain slices, on epileptic activity in in vivo models,
i.e., in animals that were made epileptic with chemoconvulsant treatment, and in epileptic patients.
These studies reveal that neurosteroids can modulate ictogenesis and the occurrence of pathological
network activity such as interictal spikes and high-frequency oscillations (80–500 Hz). Moreover,
they can delay the onset of spontaneous seizures in animal models of mesial temporal lobe epilepsy.
Overall, this evidence suggests that neurosteroids represent a new target for the treatment of focal
epileptic disorders.
Keywords: neurosteroids; epilepsy; allopregnanolone; allotetrahydrodeoxycorticosterone; GABA;
epileptogenesis; ictogenesis
1. Introduction
Neurosteroids are a class of compounds that modulate neuronal excitability at the level of ion
channels and membrane receptors [1–3]. They fall into three main classes, i.e., sulfated, pregnane,
and androstane neurosteroids [4]. The first class exerts excitatory effects, while the latter two play
inhibitory roles [4,5]. For instance, sulfated neurosteroids can increase neuronal excitability by interacting
with the picrotoxin (PTX) site of the GABAA receptor [6,7] or by acting as a positive allosteric modulator
of the NMDA receptor [8]. In contrast, pregnane neurosteroids, such as allopregnanolone, pregnanolone
and allotetrahydrodeoxycorticosterone (THDOC), positively modulate GABAA signaling [9]. Given the
role of GABA-mediated activity in epileptic disorders, pregnane neurosteroids can act as broad
spectrum anti-convulsants [10–17] that modulate the efficacy of GABAA receptor function to enhance
inhibition in the brain [18–22]. Allopregnanolone and THDOC are synthesized in the brain from
the transformation of cholesterol into pregnenolone by the cytochrome P450 cholesterol side chain
cleavage (P450scc), independently of peripheral organs such as the ovaries and adrenal glands [2].
Accordingly, P450scc is expressed in various brain regions, such as the amygdala, hippocampus,
thalamus, hypothalamus, cortex, cerebellum and olfactory bulb [2,3,23,24]. P450scc is mostly located
in glial cells and principal neurons, whereas its expression is limited in interneurons [2,4,11,23].
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In 1986, Majewska et al. discovered that allopregnanolone is a potent allosteric modulator of
GABAA receptors [4,25]. In 1997, Zhu and Vicini [26] found that THDOC increases the open probability
of GABAA receptor channels by facilitating late channel openings, while, a few years later, it was shown
that it can potentiate both GABAA receptor phasic and tonic currents [10,27]. It is worth noting that
the presence of the δ subunit in the GABAA receptor confers greater transduction of the neurosteroids’
action [27,28]. GABAA receptors containing the δ subunit are mainly found extrasynaptically, are more
resistant than synaptic receptors to desensitization and have a low affinity to GABA, even at saturating
concentrations [27,29]. Allopregnanolone and THDOC can enhance the tonic current generated by
activating these δ GABAA receptors [30,31].
We will review here recent evidence showing that neurosteroids can modulate epileptiform
synchronization in vitro, as well as ictal and interictal activities in animal models of mesial temporal
lobe epilepsy (MTLE) and in epileptic patients. In addition, neurosteroids appear to be able to alter the
processes leading to epileptogenesis. Overall, these studies lead us to conclude that neurosteroids may
represent a new therapeutic target for the treatment of human focal epileptic disorders.
2. Effects on 4-Aminopyridine-Induced Epileptiform Synchronization In Vitro
An early in vitro study performed in rat hippocampal slices reported that the neurosteroid
allopregnanolone (5α-pregnan-3α-ol-20-one), its 5β-epimer pregnanolone and pregnenolone sulfate
can modulate the spontaneous interictal-like epileptiform discharges induced in the CA3 region by
the GABAA receptor antagonist picrotoxin or the voltage-gated K+ channel blocker 4-aminopyridine
(4AP) [32]. 4AP is known to indirectly enhance Ca2+ entry into presynaptic nerve terminals,
thus increasing neurotransmitter release at both excitatory and inhibitory synapses (see for a review
Avoli et al. [33]; Avoli and de Curtis [34]). In this study, Salazar et al. [32] found a concentration-dependent
ability of allopregnanolone to reduce both PTX- and 4AP-induced interictal spiking while 5β-epimer
pregnanolone failed to alter PTX-induced but was partially effective on the 4AP-induced activity.
In addition, pregnenolone sulfate increased the frequency of both PTX-induced bursting, while in the
4AP model it increased the frequency of a specific type of interictal event [32].
It is well established that 4AP induces two types of spontaneous interictal discharges—which have
been identified as fast and slow events—in the isolated hippocampal slice preparation [35]. The fast
events (arrows in Figure 1A, CA3 trace) mirror the synchronous discharge of CA3 pyramidal cells
that are interconnected through glutamatergic excitatory synapses, while the slow events (asterisks in
Figure 1A, CA3 trace) mainly reflect the synchronous firing of inhibitory interneurons leading to GABA
release and subsequent activation of GABA receptor subtypes. In keeping with this view, 4AP-induced
slow interictal events disappear during GABAA receptor antagonism, while they continue to occur
and propagate in the absence of glutamate-mediated synaptic transmission; it has been proposed that
these latter, glutamatergic-independent phenomena depend on gap-junctions and the excitatory effects
caused by the concomitant occurrence of transient elevations in [K+] (see for review Avoli et al. [33];
Avoli and de Curtis [34]).
More complex patterns of spontaneous epileptiform discharge are, however, recorded during
4AP application in extended brain slices that include limbic or olfactory cortical structures [33,34].
As shown in Figure 1Aa (grey bar), in addition to the two types of interictal discharge (panel b and c),
prolonged periods of epileptiform synchronization—which resemble ictal events—can occur in
combined hippocampus-entorhinal cortex slices [36]. These ictal discharges appear to initiate in
the entorhinal or perirhinal cortices as well as in the amygdala depending on the type of cut used
to obtain extended brain slices that include specific areas. Moreover, both slow interictal and ictal
discharges have been recorded from the piriform (Figure 1B, (grey bars) [37], insular [38] or cingulate
cortices [39] in in vitro rodent brain slices. Finally, as reported in EEG recordings obtained in vivo from
epileptic patients [40–42] or rodents [40,43], the epileptiform activity generated in vitro by brain slices
is characterized by the occurrence of high frequency oscillations (HFOs, 80–500 Hz).
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Figure 1. Epileptiform patterns induced by 4-aminopyridine (4AP) in rodent brain slices including 
the hippocampus-entorhinal cortex or the piriform cortex. (A): In panel (a), simultaneous field 
potential recordings obtained from the entorhinal cortex (EC), dentate gyrus (DG) and CA3 subfield 
of the hippocampus show the occurrence of three different types of epileptiform activity; the first 
(grey line)—which is recorded synchronously in all areas—consists of sustained discharge resembling 
a focal ictal discharge; the second type (asterisks) occurs in all areas and is characterized by slow 
interictal spikes; the third type (arrows) consists of continuous fast interictal-like events that are 
recorded in the CA3 subfield. Expanded traces of one fast and one slow interictal spike are shown in 
panels (b) and (c), respectively. (B): In panel (a), simultaneous field potential recordings obtained 
from the anterior and posterior portions of the piriform cortex in a sagittal slice; electrodes were 
positioned in layers I, II and III, as shown in the slice drawing. Note that both focal ictal discharges 
(grey lines) and interictal spikes (asterisks) occur spontaneously; two interictal spikes are expanded 
in panels (b) and (c). Panels shown in (A) and (B) are modified from the studies by Avoli et al. [36] 
and by Panuccio et al. [37], respectively. 
HFOs are not visible in standard field potential recordings and can only be extracted by 
amplifying the appropriately filtered signal. Pathological HFOs—which have been categorized 
according to their frequency as ripples (80–200 Hz) and fast ripples (250–500 Hz)—presumably reflect 
the activity of dysfunctional neural networks sustaining epileptic discharges, and they are now 
considered better markers than interictal spikes to identify seizure onset zones [44]. Several 
mechanisms may contribute to HFOs, and their exact roles remain elusive; however, it has been 
proposed that ripples may represent population-inhibitory postsynaptic potentials generated by 
principal neurons entrained by synchronously active interneuron networks [45,46]; in contrast, fast 
ripples should mirror in-phase or out-of-phase synchronous firing of abnormally active principal 
cells, and they would be independent of inhibitory neurotransmission [47–51]. 
Figure 1. Epileptiform patterns induced by 4-aminopyridine (4AP) in rodent brain slices including
the hippocampus-entorhinal cortex or the piriform cortex. (A): In panel (a), simultaneous field
potential recordings obtained from the entorhinal cortex (EC), dentate gyrus (DG) and CA3 subfield
of the hippocampus show the occurrence of three different types of epileptiform activity; the first
(grey line)—which is recorded synchronously in all areas—consists of sustained discharge resembling a
focal ictal discharge; the second type (asterisks) occurs in all areas and is characterized by slow interictal
spikes; the third type (arrows) consists of continuous fast interictal-like events that are recorded in the
CA3 subfield. Expanded traces of one fast and one slow i terictal spike are shown in panels (b) and (c),
respectively. (B): In panel (a), simultaneous field potential recordings obtained from the anterior and
osterior portions of the piriform cortex in a sagittal slice; electrodes were position d in layers I, II an
III, as shown in the slice drawing. Note that both focal ictal discharges (grey line ) and inte ictal spikes
(asterisks) occur spontaneously; two interictal spikes a e expanded in panels (b, ). Panels shown in
(A,B) ar modified f om the studie by Avoli et al. [36] and by Panuccio et al. [37], respectively.
HFOs are not visible in standard field potential recordings and can only be extracted by amplifying
the appropriately filtered signal. Pathological HFOs—which have been categorized according to their
frequency as ripples (80–200 Hz) and fast ripples (250–500 Hz)—presum bly reflect the activity of
dysfunctional neural networks sustainin epileptic disch rges, and they are now consider d better
markers than interictal spikes to identify seizure onset zones [44]. Several mechanisms may contribute
to HFOs, and their exact roles remain elusive; however, it has been propo ed that ripples may
repres nt population-inhibitory postsynaptic ot ntials generated by principal neurons entrained by
synchronously ctive intern uron networks [45,46]; in contrast, fast ripple should mirror in-phas or
out-of-phase synchronous firing of abnormally active principal cell , and they would be independent
of inhibitory neurotransmission [47–51].
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During the last few years, we have employed extended rat brain slices—which included either
the piriform cortex or the entorhinal cortex—to analyze the ability of the neurosteroid THDOC to
influence the epileptiform activity induced by 4AP in non-epileptic control (NEC) (Figure 2A) and
pilocarpine-treated animals (Figure 2B) [15,17]. THDOC is known to enhance brain inhibition [52] and
to induce anticonvulsant effects in vivo [10,19,53,54] (see also Section 3). As shown in Figure 2A,C,D,
THDOC decreased the duration of the ictal discharges while prolonging the interictal spikes recorded
in brain slices that had been obtained from NEC rats and included the piriform cortex or the entorhinal
cortex. In addition, when analyzing ripples and fast ripples associated to 4AP-induced ictal discharges in
the piriform (Figure 3A) and entorhinal cortex (Figure 3B), we found in these experiments that THDOC
decreased the occurrence of fast ripples that were associated with interictal spikes (Figure 3C). THDOC,
however, induced in pilocarpine-treated animals a significant increase of ripples in the piriform and
entorhinal cortices and a significant increase of fast ripples in the piriform cortex (Figure 3C,D). Overall,
these results demonstrate that THDOC plays a modulatory role on the epileptiform synchronization
and that its effects are structure-dependent and more pronounced in epileptic than in NEC tissue.
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Figure 2. (A): Effects induced by allotetrahydrodeoxycorticosterone (THDOC) on the 4AP-induced 
epileptiform activity generated in vitro by the piriform cortex obtained from non-epileptic control 
(NEC) rodents. Note that both interictal (enlarged sample) and ictal discharges can be recorded 
during application of 4AP and following the addition of THDOC. (B): 4AP-induced interictal and ictal 
discharges recorded from the piriform cortex of brain slices obtained from epileptic (Pilocarpine-
treated) rodents in 4AP and following bath application of THDOC. (C): Quantification of the interictal 
events and ictal events recorded from the piriform cortex during 4AP application and after 
application of THDOC in brain slices obtained from NEC and pilocarpine-treated animals. (D): 
Quantification of the interictal and ictal events recorded from the entorhinal cortex during 4AP 
application and after application of THDOC in brain slices obtained from NEC and pilocarpine-
treated animals. * indicates p < 0.05; ** indicates p < 0.01. Panels shown in this figure are modified from 
the study by Shiri et al. [17]. 
Figure 2. ( ): Effects induced by allotetrahydrodeoxycorticosterone (T ) on the 4 P-induced
epileptifor activity generated in vitro by the pirifor cortex obtained fro non-epileptic control
(NEC) rodents. Note that both interictal (enlarged sa ple) and ictal discharges can be recorded
during application of 4AP and following the addition of THDOC. (B): 4AP-induced interictal and ictal
discharges recorded from the piriform cortex of brain slices obtained from epileptic (Pilocarpine-treated)
rodents in 4AP and following bath application of THDOC. (C): Quantification of the interictal events
and ictal events recorded from the piriform cortex during 4AP application and after application of
THDOC in brain slices obtained from NEC and pilocarpine-treated animals. (D): Quantification of
the interictal and ictal events recorded from the entorhinal cortex during 4AP application and after
application of THDOC in brain slices obtained from NEC and pilocarpine-treated animals. * indicates
p < 0.05; ** indicates p < 0.01. Panels shown in this figure are modified from the study by Shiri et al. [17].
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entorhinal cortex (B); field potential recordings showing interictal events co-occurring with ripples 
and fast ripples are shown in panels (a) and (b), respectively. (C) and (D): Quantification of the effects 
induced by THDOC on the ripples and fast ripples associated with 4AP-induced interictal events 
recorded from the piriform and entorhinal cortex of brain slices that were obtained from NEC and 
pilocarpine-treated rats. Note that THDOC increases the association of ripples with the interictal 
discharges occurring in both the piriform and entorhinal cortex of epileptic animals; THDOC also 
decreases and increases fast ripple occurrence in the piriform cortex of NEC and epileptic brain slices, 
respectively, but does not induce any significant change in fast ripples recorded from the entorhinal 
cortex. * indicates p < 0.05; ** indicates p < 0.01. Panels shown in this figure are modified from the 
study by Shiri et al. [17]. 
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events that were recorded during a pharmacological blockade of glutamatergic transmission but had 
no effect on the interictal pattern that was generated during GABAA receptor antagonism. Therefore, 
these results suggest that potentiation of GABAA receptor-mediated signaling by THDOC 
differentially affects slow and fast interictal discharges. It was also found in this study [15] that HFOs 
were modulated by THDOC. In addition, when it was applied to 4AP-treated slices, THDOC led to 
an increase in ripple occurrence without any concomitant change in fast ripple activity, thus 
indicating that it increases GABA-receptor mediated function. As already mentioned, ripples 
presumably reflect the synchronous activity of GABAergic interneurons [46,55–57]. Note that the 
amplitude of ripples and fast ripples associated with the interictal spikes was also increased by 
THDOC; such effects could reflect the increased recruitment of synchronized pyramidal cells [15], 
although this hypothesis needs to be confirmed. 
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and neuronal-subtype-specific manner, which ultimately affects both phasic and tonic inhibitory 
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Herrington et al. [15] also found that THDOC can induce a dose-dependent decrease in the
duration of the fast interictal events recorded from the CA3 subfield of the hippocampus; in contrast,
the duration of the slow interictal spikes increased. Moreover, THDOC potentiated the slow interictal
events that were recorded during a pharmacological blockade of glutamatergic transmission but had
no effect on the interictal pattern that was generated during GABAA receptor antagonism. Therefore,
these results suggest that potentiation of GABAA receptor-mediated signaling by THDOC differentially
affects slow and fast interictal discharges. It was also found in this study [15] that HFOs were modulated
by THDOC. In addition, when it was applied to 4AP-treated slices, THDOC led to an increase in
ripple occurrence without any concomitant change in fast ripple activity, thus indicating that it
increases GABA-receptor mediated function. As already mentioned, ripples presumably reflect the
synchronous activity of GABAergic interneurons [46,55–57]. Note that the amplitude of ripples and
fast ripples associated with the interictal spikes was also increased by THDOC; such effects could
reflect the increased recruitment of synchronized pyramidal cells [15], although this hypothesis needs
to be confirmed.
3. Effects in Animal Models of Mesial Temporal Lobe Epilepsy In Vivo
In animal models of focal epil psy, GABAA receptor expressio is extensively altered in a region-
and neuronal-subtype-specific manner, which ultimately affects both phasic and tonic inhibitory
currents [58,59]. For instance, following the induction of temporal lobe epilepsy in rats with continual
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hippocampal stimulation, the δ subunit-containing receptor expression is reduced in dentate gyrus
granule cells, while there is an increase in the expression of α4γ2-containing subunits [60]. The increase
in α4γ2-containing subunits presumably acts as a compensatory mechanism for the initial reduction in
tonic inhibition. Similar findings were also observed in pilocarpine-treated mice, but these authors
also found that δ subunit containing receptor expression increased in hippocampal interneurons [61].
Furthermore, dentate gyrus granule cells exhibit an increase in the expression of synaptic GABAA
receptors, which is coupled with a reduced sensitivity to benzodiazepines [62]. The down-regulation
of the δ subunit-containing receptors suggests that temporal lobe epilepsy may be associated with
reduced levels of neurosteroid sensitivity [62]. Additional mechanisms in epileptic animals that can
alter neurosteroid sensitivity include a loss of GABAergic neurons in the subiculum [63,64] and a shift
in inhibition such that principal cell GABAergic input is reduced, while interneuronal GABAergic
input is enhanced in the piriform cortex [65].
Høgskilde et al. [66] were the first to demonstrate in vivo that a systemic pre-administration of
pregnanolone could protect against acute seizures induced with several chemoconvulsants, such as
pentetrazole, bicuculline, picrotoxin and strychnine. Similar results were obtained by Belelli et al. [67],
who also reported that more potent anti-ictogenic effects were obtained when allopregnanolone was
administered before the GABAA receptor antagonist bicuculline. Allopregnanolone was, however,
ineffective in the maximal electroshock model and against strychnine-induced seizures, as later
confirmed by Kokate et al. [68]. Further studies also showed that allopregnanolone induces a
dose-dependent protection against seizures in the 6 Hz and pentylenetetrazole model, as well as partial
protection against NMDA-induced seizures [68–70].
The anti-ictogenic properties of neurosteroids are not only observed in acute seizure models,
but also in chronic animal models of MTLE, such as in the pilocarpine and kainic acid model.
Pilocarpine is a cholinergic muscarinic agonist that when systemically injected in rodents, induces a
status epilepticus (SE) that is followed by a latent period—during which no seizures are observed—and
then by recurrent, spontaneous non-convulsive and convulsive seizures [71,72]. Kainic acid—which is
a cyclic analog of L-glutamate and an agonist of the ionotropic kainate receptor—when administered
locally or systemically in rodents, also induces an SE that is followed by a latent period and then
by the occurrence of spontaneous focal seizures that can become secondarily generalized [73–76].
Kokate et al. [70] have shown that allopregnanolone and THDOC can prevent the development of
pilocarpine-induced SE in rodents. Furthermore, when administered 15 min after the onset of SE,
pregnanolone completely abolished ictal activity. Saporito et al. [77] recently reported that such
effects can be observed when allopregnanolone or ganaxolone (the 3β-methylated synthetic analog of
allopregnanolone) are administered 15 min after SE onset in the lithium-pilocarpine model. Ganaxolone
had similar anti-ictogenic properties when administered 60 min after SE onset, whereas only transient
effects were observed with allopregnanolone [77].
Kokate et al. have also reported that pregnanolone and THDOC provide protection against
the development of kainic acid-induced SE in mice [70]. However, neurosteroids had less potent
anti-ictogenic effects in this model than in the pilocarpine model. According to these investigators,
this difference should be due to the prolonged duration of the kainic acid-induced SE as compared
to pilocarpine-induced SE; in line with their view, they found that a second administration of the
investigated neurosteroid 1 h after the first dose was needed to obtain a complete anti-ictogenic effect
in the kainic acid model [70].
Although neurosteroid levels can significantly modulate SE in animal models of MTLE, it was
unclear until a few years ago whether they also display any relationships with the duration of the
latent period and the occurrence of spontaneous seizures. Evidence obtained by Biagini et al. [78] now
suggests that the duration of the latent period, as well as P450scc induction, is indeed increased in
animals that have endured prolonged pilocarpine-induced SE. However, when neurosteroid synthesis
is blocked with finasteride, the duration of the latent period is decreased [78], suggesting that by
increasing GABA-mediated inhibition, neurosteroids can delay the development of a chronic epileptic
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condition, as was proposed before in the kindling model of epileptogenesis [79]. The same group then
performed further analyses of P450scc immunoreactivity in the hippocampus of pilocarpine-treated
rodents and found that it is expressed in several glial cells including astrocytes, oligodendrocytes
and microglia [80]. In the same study, they also found that inhibition of neurosteroids with a daily
administration of finasteride between day 4 and day 28 after SE could accelerate the development of
spontaneous seizures, but only in animals that experienced an SE that lasted for more than 3 h and that
exhibited significant increases of P450scc induction. In line with these findings, Joshi et al. [81] used
the lithium-pilocarpine model to demonstrate that a single administration of finasteride on the fourth
day after a 2 h SE is sufficient to decrease the duration of the latent period; according to these authors,
this suggests that inhibition of neurosteroids must be performed at the time of down-regulation of
δ-GABA receptor expression, which occurs between SE and the onset of spontaneous seizures.
Since allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic modulator
of GABAA receptors, its administration could functionally reverse the GABAergic deficit that may
occur after SE. Lévesque et al. [14], therefore, assessed whether its administration during the latent
phase could modulate spontaneous seizures in the pilocarpine rat model of MTLE. In their study,
allopregnanolone was administered with a subcutaneous pump for 12 consecutive days starting 1 day
after SE. Compared to the untreated group, in which 67% of them became epileptic, only 29% of
allopregnanolone-treated animals were epileptic. These anti-epileptogenic effects were associated
to significantly lower rates of interictal spikes in the CA3 and entorhinal cortex of non-epileptic
allopregnanolone-treated animals compared to the untreated group (Figure 4A–C). Rates of interictal
spikes with fast ripples (Figure 4D) were also significantly lower in the allopregnanolone-treated
group compared to the untreated group (Figure 4E), whereas rates of interictal spikes with ripples
(Figure 4D) were not significantly different between groups (Figure 4F). Interestingly, the effects induced
by allopregnanolone were similar to those observed with the anti-epileptic drugs levetiracetam and
lacosamide in the pilocarpine model of MTLE [82,83], confirming the potential of GABAA receptor
modulating neurosteroids in the treatment of epilepsy.
Endogenous levels of allopregnanolone and pregnanolone in the brain of rats that have been
treated with kainic acid to induce an SE are also significantly modulated by spontaneous seizures.
Lucchi et al. [84] recently observed reduced levels of allopregnanolone and pregnanolone in the
hippocampus of epileptic animals 9 weeks after SE. Moreover, linear regression analyses revealed a
significant positive correlation between endogenous levels of allopregnanolone and seizure frequency
in the hippocampus (higher seizure rates of seizures were associated with increased levels of
allopregnanolone), whereas this correlation was not observed in the neocortex. No significant
correlations were observed between endogenous levels of pregnanolone and the frequency of
spontaneous seizures and no alterations in circulating levels of allopregnanolone and pregnanolone were
observed. It was, therefore, hypothesized that focal allopregnanolone synthesis in the hippocampus is
increased in the presence of seizures as a compensatory mechanism, but that it fails in restoring levels
of this neurosteroid.
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Figure 4. (A): Representative EEG recordings from the CA3 region of the hippocampus and the 
entorhinal cortex (EC) of an epileptic untreated animal. (B): Representative recordings in an epileptic 
animal that was treated with allopregnanolone. Insets (a) show interictal spikes (asterisks) on a lower 
timescale. (C): Bar graphs showing rates of interictal spikes in the epileptic untreated and non-
epileptic allopregnanolone-treated group. Rates of interictal spikes in CA3 and EC were significantly 
lower in the non-epileptic allopregnanolone-treated group compared to the epileptic untreated group 
(* p < 0.05). (D): Example of a ripple (80–200 Hz) and a fast ripple (250–500 Hz) that occurred in 
association with an interictal spike, in an epileptic untreated animal. The wavelet analysis is shown 
to illustrate ripples and fast ripples (white arrows). (E): Bar graph showing ratios of interictal spikes 
with fast ripples on the total number of interictal spikes. In both CA3 and EC, rates of interictal spikes 
with fast ripples occurred at significantly lower rates in the non-epileptic allopregnanolone-treated 
group compared to the epileptic untreated group (* p < 0.05). (F): Bar graph showing ratios of interictal 
spikes with ripples on the total number of interictal spikes. No significant differences were observed 
between groups. Panels were modified from the study of Lévesque et al. [14]. 
Figure 4. (A): Representative EE recordings from the CA3 region of the hippocampus and the
entorhinal cortex (EC) of an epileptic untreated animal. (B): Representative recordings in an epileptic
animal that was treated with allopregnanolone. Insets (a) show interictal spikes (asterisks) on a lower
timescale. (C): Bar graphs showing rates of interictal spikes in the epileptic untreated and non-epileptic
allopregnanolone-treated group. Rates of interictal spikes in CA3 and EC were significantly lower in the
non-epileptic allopregnanolone-treated group compared to the epileptic untreated group (* p < 0.05).
(D): Example of a ripple (80–200 Hz) a d a fast ripple (250–500 Hz) that occurred in as ociation with an
interictal pik , n an epileptic untreated animal. The wavelet analysis is shown to illustrate ripples
and fast ripples (white arrows). (E): Bar graph showing ratios of interictal spikes with fast ripples on
the total number of interictal spikes. In both CA3 and EC, rates of interictal spikes with fast ripples
occurred at significantly lower rates in the non-epileptic allopregnanolone-treated group compared to
the epileptic untreated group (* p < 0.05). (F): Bar graph showing ratios of interictal spikes with ripples
on the total number of interictal spikes. No significant differences were observed between groups.
Panels were modified from the study of Lévesque et al. [14].
4. Human Studies
The possible therapeutic use of neurosteroids for epilepsy was first explored in pediatric patients
treated with the methylated analog of allopregnanolone, ganaxolone [85]. These authors examined
15 patients within the range of 5–15 years of age, suffering from drug-resistant epilepsy of various
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types; eight of them concluded the trial, at the end of which beneficial effects were observed in six
patients. This pilot study was then followed by another one performed in adults with partial-onset
seizures that were poorly controlled by antiepileptic drugs [86]. In this study, 131 patients completed
the protocol (86 maintained on ganaxolone) and a reduction of about 11% in the seizure frequency was
observed with ganaxolone. The most common adverse events were dizziness, fatigue and somnolence,
found in approximately 15% of cases. Additionally, in view of the reduction in allopregnanololone
and other steroid levels in patients with protocadherin 19 (PCDH19)—female limited epilepsy [87],
trial is currently ongoing to evaluate if ganaxolone may be beneficial in patients with this rare
neurological disorder [88]. However, caution on the effectiveness of the use of allopregnanolone
analogues has been raised by a study on post mortem neocortical tissue obtained from children with
epilepsy, in which authors found an altered composition of GABAA receptors leading to reduced
sensitivity to neurosteroids [89]. Therefore, these results suggest that children could be unresponsive
to allopregnanolone analogues.
Unsatisfactorily, the allopregnanolone analog brenaxolone has been tested in patients with
refractory or super-refractory SE [90]. After having successfully passed a phase I/II trial [91],
a phase III trial did not find any beneficial effect of brexanolone (reported in Rossetti et al. [90]).
However, Meletti et al. [92,93] found a marked reduction in progesterone, 5α-dihydroprogesterone,
allopregnanolone and pregnanolone levels in the cerebrospinal fluid obtained by patients with SE,
thus suggesting that administration of allopregnanolone or the analogs alone could be insufficient to
reach an adequate compensation for the reported defect in various neurosteroid levels. In this regard,
a more effective approach to re-establish normal levels of anticonvulsant neurosteroids should be
made available. Such a goal could be possibly achieved by using trilostane, an inhibitor of peripheral
conversion of pregnenolone to progesterone, which was found to increase the cerebral levels of different
neurosteroids [94,95]. Recently, pretreatment with trilostane was shown to increase the neocortical and
hippocampal levels of pregnenolone, progesterone, 5α-dihydroprogesterone and allopregnanolone,
leading to the reduction in convulsive seizure duration in rats with kainic acid-induced SE [96].
Finally, progesterone is known to be effective in catamenial epilepsy, i.e., epileptic women who
experience perimenstrual seizure exacerbation [97]. This effect could be related to the conversion
of progesterone to allopregnanolone, as suggested by a case report in which a woman, cured with
progesterone, developed refractoriness to antiepileptic drugs when she was treated with finasteride [98].
However, the appearance of resistance to antiepileptic drugs has been also reported in a woman who
was treated with finasteride but did not receive progesterone as an add-on drug. This finding suggests
that allopregnanolone levels might influence the response to the antiepileptic treatment [99].
5. Conclusions
We have reviewed here some experimental and clinical studies that were aimed at establishing
the involvement of neurosteroids in the context of focal epileptic disorders. Clearly, the modulatory
effects exerted by these compounds depends on their class (e.g., sulfated vs. nonsulfated), the subunit
composition of the neurotransmitter receptors as well as the pathophysiological mechanisms that
underlie specific epileptic disorders. For instance, much of the experimental evidence suggests that
the ability of neurosteroids to influence neuronal excitability resides primarily in the enhancement of
GABAA receptor function. On the other hand, this physiological characteristic may result in opposite
effects, depending on the contribution of GABAergic mechanisms to epileptiform synchronization [100].
Finally, it remains to be firmly established whether neurosteroids or their analogues can prevent the
development of a chronic epileptic condition (i.e., whether they can successfully halt epileptogenesis).
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